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abstract
PURPOSE Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea
and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI resumption.
METHODS This retrospective multicenter study examined patients who resumed ICI therapy after improvement of
IMDC between January 2010 and November 2018. Univariable and multivariable logistic regression analyses
assessed the association of clinical covariates and IMDC recurrence.
RESULTS Of the 167 patients in our analysis, 32 resumed an anti–cytotoxic T-cell lymphocyte-4 (CTLA-4) agent,
and 135 an anti–programmed cell death 1 or ligand 1 (PD-1/L1) agent. The median age was 60 years
(interquartile range [IQR], 50-69 years). The median duration from IMDC to restart of ICI treatment was 49 days
(IQR, 23-136 days). IMDC recurred in 57 patients (34%) overall (44% of those receiving an anti–CTLA-4 and
32% of those receiving an anti–PD-1/L1); 47 of these patients (82%) required immunosuppressive therapy for
recurrent IMDC, and all required permanent discontinuation of ICI therapy. The median duration from ICI
resumption to IMDC recurrence was 53 days (IQR, 22-138 days). On multivariable logistic regression, patients
who received anti–PD-1/L1 therapy at initial IMDC had a higher risk of IMDC recurrence (odds ratio [OR], 3.45;
95% CI, 1.59 to 7.69; P = .002). Risk of IMDC recurrence was higher for patients who required immuno-
suppression for initial IMDC (OR, 3.22; 95% CI, 1.08 to 9.62; P = .019) or had a longer duration of IMDC
symptoms in the initial episode (OR, 1.01; 95% CI, 1.00 to 1.03; P = .031). Risk of IMDC recurrence was lower
after resumption of anti–PD-1/L1 therapy than after resumption of anti–CTLA-4 therapy (OR, 0.30; 95% CI, 0.11
to 0.81; P = .019).
CONCLUSION One third of patients who resumed ICI treatment after IMDC experienced recurrent IMDC. Re-
currence of IMDC was less frequent after resumption of anti–PD-1/L1 than after resumption of anti–CTLA-4.
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INTRODUCTION
Immune checkpoint inhibitors (ICIs) have revolution-
ized cancer therapy and have been the focus of in-
tensive clinical and basic research in recent years. ICIs
augment antitumor immune response by blocking cy-
totoxic T-cell lymphocyte-4 (CTLA-4) or programmed
cell death 1 or ligand-1 (PD-1/L1) or both, resulting in
significant response rates in a subset of malignancies.1
Currently, studies are assessing ICI safety and efficacy
in an increasing array of solid tumors as well as he-
matologic malignancies.2
The toxicity profile of ICIs is distinct from those of
other cancer therapies and falls under the umbrella
term immune-related adverse events (irAEs) because
of their autoimmune nature.1 In theory, irAEs can
affect any organ system and frequently manifest as
dermatitis, diarrhea, colitis, pneumonitis, hepatitis,
and pancreatitis.3 Development of irAEs is indicative
of an augmented immune response, which is asso-
ciated with prolonged overall survival, and should be
considered a surrogate marker for positive response
to ICI therapy.4-6 We previously reported longer overall
survival among patients who develop immune-
mediated diarrhea and colitis (IMDC).5,6 However,
considerable controversy exists with regard to the
impact of irAEs on survival because some investigators
have not found a similar impact.7,8
IMDC can be severe enough to cause colon perforation
and death if not treated appropriately.9 Therefore,
timely and precise management of IMDC is critical
for favorable outcomes.10-12 Current treatment guide-
lines recommend holding ICI therapy in patients with
grade 2 or higher IMDC and initiating corticosteroid
therapy.13-15 A subset of these patients may resume
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symptoms subside to grade 1. Furthermore, it may be
possible to hold ICI therapy temporarily (in cases of
cancer progression) or indefinitely (in cases of cancer
remission) because the optimum number of doses of
anti–PD-1/L1 remains unknown. However, a paucity of
evidence exists on the safety profile of ICI resumption in
patients who stopped treatment because of the de-
velopment of an irAE.
One large-scale study that assessed the safety of resuming
anti–PD-1 therapy included 80 patients previously treated
with a combination anti–CTLA-4 and anti–PD-1 ICI regimen
who developed a treatment-limiting irAE.16 Although the
findings were encouraging and have added to the current
body of evidence, they did not address patients who were
previously treated with anti–PD-1/L1 or anti–CTLA-4 ther-
apy as a single agent and then resumed the same or
a different ICI agent. Because IMDC frequently requires
interruption of ICI treatment, the current study aimed to
identify the incidence and characteristics of and risk factors
for recurrent IMDC after resumption of ICI therapy in pa-




This retrospective multicenter study was approved by the
institutional review boards of the participating institutions
(Appendix Table A1, online only). Included patients were
18 years of age or older who received an ICI and developed
IMDC between January 2010 and November 2018 and
then resumed ICI therapy after it was suspended because
of IMDC onset. Patients were identified from pharmacy and
institutional databases.
Clinical Data
Demographic information, medical and oncologic history,
and data related to ICI therapy and IMDC were extracted
from the medical record of each identified patient.
Comorbid conditions included in the Charlson comorbidity
index score were recorded.17 Cancer stage was determined
according to the seventh edition of the American Joint
Committee on Cancer Staging System but was not recorded
for patients with hematologic malignancies because of the
intricate staging systems used.
ICI and IMDC Information
The recorded information that pertained to ICI included
type, number of infusions, and duration of treatment. In
addition, we documented the reason for resuming ICI
therapy after IMDC as cancer progression, resolution of
irAE, or maintenance therapy. Cancer progression was
assessed as reported in the medical chart by the treating
oncologist and radiologist according to the immune-
modified Response Evaluation Criteria in Solid Tumors
(imRECIST) and immune RECIST (iRECIST).18,19 The
Common Terminology Criteria of Adverse Events (version
5.0) was used to grade IMDC at its peak severity.20 The
duration of IMDC symptoms was measured as the cu-
mulative number of days from IMDC onset until symptom
resolution.
Clinical Outcomes
The primary end point of this study was recurrence of IMDC
after resuming ICI therapy. Time from IMDC occurrence to
ICI restart, type of ICI restarted, reason to restart ICI, time
from ICI restart to IMDC recurrence (if any), peak grade of
the recurrent IMDC, and treatment required for the re-
current IMDC were recorded.
Statistical Analyses
The distributions of continuous variables were summarized
using medians and interquartile ranges (IQRs). The dis-
tributions of categorical variables were summarized using
frequencies and percentages. Categorical variables were
compared between groups by Fisher’s exact and x2 tests.
Continuous variables were compared by Wilcoxon rank
sum test. To assess the risk factors for IMDC recurrence, we
performed a univariable followed by a multivariable logistic
regression. Clinical characteristics that were significant in
the univariable analysis or were relevant to clinical practice
(ie, type of ICI resumed) were included in the multivariable
model. Requirement for infliximab or vedolizumab was
not added to the multivariable analysis because its ef-
fect is included as part of immunosuppression. Hosmer-
Lemeshow test was used to measure the goodness of fit
of the included variables in the multivariable logistic re-
gression model and revealed P = .22, which indicates
a good fit of the variables in the multivariable logistic model.
In addition, collinearity was evaluated using the variance
inflation factor, which assesses how much the variance of
an estimated regression coefficient increases if the pre-
dictors are correlated. The highest variance inflation factor
for our model was 1.66, which indicates that there was no
multicollinearity. All statistical tests were two-sided. P# .05
was considered statistically significant. Statistical analyses
were carried out using SAS 9.4 (SAS Institute, Cary, NC)




Among 550 patients who had IMDC, we identified 167
(30%) who received ICI treatment after the onset of IMDC;
patient demographic and clinical characteristics are
listed in Table 1. The median age was 60 years (IQR, 50-69
years). Initial ICI therapy was a PD-1/L1 inhibitor in 79
patients (47%), a CTLA-4 inhibitor in 47 (28%), and
a combination in 41 (25%). Melanoma was the most
common malignancy type in this cohort (54%) followed
by non–small-cell lung cancer (16%) and genitourinary
cancer (10%).
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Initial IMDC and Non-GI irAEs
The median duration of initial IMDC symptoms was 12 days
(IQR, 5-28 days). Seventy-five patients had an endoscopic
evaluation. A majority of the patients who developed IMDC
required immunosuppression with a corticosteroid (113;
68%); among them, 24 patients (14%) required treatment
escalation to addition of infliximab or vedolizumab. Non-GI
irAEs were reported in 72 patients (43%) and involved skin
(n = 22), liver (n = 11), endocrine organs (n = 29), lung
(n = 9), or other sites (n = 19).
ICI Resumption and IMDC Recurrence
ICI therapy was re-initiated because of cancer progression
or relapse in 48 patients (29%), whereas 119 (71%) either
continued therapy as maintenance therapy with good re-
sponse to ICI or resumed therapy after irAE resolution. The
median duration from initial IMDC to ICI resumption was
49 days (IQR, 23-136 days). On resuming ICI therapy,
a majority of patients received an anti–PD-1/L1 agent (135;
81%), whereas 32 (19%) received an anti–CTLA-4 agent
(Table 2). Overall, IMDC recurred in 57 patients (34%) after
a median of 53 days (IQR, 22-138 days) after ICI re-
sumption. Of the 57 patients who experienced IMDC re-
currence, the majority experienced grade 2 diarrhea (40;
70%) and grade 1 colitis (30; 54%). Most IMDC re-
currences required corticosteroid therapy (46; 81%).
Seven patients (12%) required treatment escalation to ad-
dition of infliximab or vedolizumab for the recurrent
IMDC.
Of the 43 patients (32%) who experienced IMDC recurrence
after resuming anti–PD-1/L1 therapy, 26 (37%) initially re-
ceived an anti–PD-1/L1 agent, and 17 (27%) initially re-
ceived an anti–CTLA-4 agent. Of the 14 patients (44%) who
experienced IMDC recurrence after resuming anti–CTLA-4
therapy, seven (88%) initially received an anti–PD-1/L1
agent, and seven (29%) initially received an anti–CTLA-4
agent (Fig 1). Monthly nivolumabwas the re-initiated ICI type
in 44 patients; among them, 10 (23%) had IMDC re-
currence. Of the 113 patients who received immunosup-
pressive therapy for initial IMDC, 47 (42%) had recurrent
IMDC. Of the seven patients who had IMDC grade 4 initially
and resumed ICI therapy (anti–CTLA-4 in two patients and
anti–PD-1/L1 in five), four (57%) had IMDC recurrence.
In patients who resumed anti–CTLA-4 therapy, IMDC re-
currence was reported after a median of 26 days (IQR, 2-43
days) and occurred significantly earlier than recurrence
after anti–PD-1/L1 resumption (median, 79 days; IQR, 27-
141 days; P = .024; Table 2). No differences were observed
in the severity of IMDC recurrence between the two groups.
The recurrence of IMDC was more severe (P , .001) and
required more intensive immunosuppressive therapy (P ,
.001) in patients who received immunosuppressive therapy
for the initial event than in those who did not (Table 3).
TABLE 1. General Characteristics of the Patient Cohort
Characteristic Patients, No. (%)
No. of patients 167
Median age, years (IQR) 60 (50-69)
Male sex 100 (60)
White race 156 (93)
Comorbid conditions present 92 (55)
Cancer type
Melanoma 90 (54)
Non–small-cell lung cancer 27 (16)
Genitourinary 17 (10)
Other solid* 26 (16)
Hematologic 7 (4)
Cancer stage (n = 160)
III 21 (13)
IV 139 (87)
Median duration of initial ICI therapy, days (IQR) 59 (25-126)













Median duration of initial IMDC symptoms, days (IQR) 12 (5-28)
Hospitalizations 78 (47)
Treatment of initial IMDC
Supportive care only 54 (32)
Corticosteroid 113 (68)
Infliximab or vedolizumab add-on 24 (14)
Non-GI adverse events of initial ICI therapy 72 (43)
Reason to re-initiate ICI therapy
Disease progression 48 (29)
Continue therapy after IMDC resolution 119 (71)
Abbreviations: CTLA-4, cytotoxic T-cell lymphocyte-4; ICI, immune checkpoint
inhibitor; IMDC, immune-mediated diarrhea and colitis; IQR, interquartile range;
PD-1/L1, programmed cell death 1 or ligand 1.
*Other solid cancer types included head and neck, Meckel cell, endocrine,
hepatobiliary, gynecologic, breast, and GI malignancies.
†Grades of diarrhea and colitis were determined by Common Terminology
Criteria for Adverse Events (version 5.0).
2740 © 2019 by American Society of Clinical Oncology Volume 37, Issue 30
Abu-Sbeih et al
Downloaded from ascopubs.org by EAST CAROLINA UNIVERSITY on April 22, 2020 from 098.235.194.237
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
Risk Factors for IMDC Recurrence
On univariable analysis (Table 4), initial use of anti–PD-1/L1
therapy (P = .034), cancer stage III (P = .049), requirement
for immunosuppressive therapy at initial IMDC (P = .003),
higher grades of IMDC (P = .007), requirement for inflix-
imab or vedolizumab at initial IMDC (P = .035), and longer
duration of initial IMDC symptoms (P = .035) were asso-
ciated with an increased likelihood of IMDC recurrence
after ICI resumption. Inflammation identified by endoscopy
in the initial IMDC episode tended to increase the risk of
IMDC recurrence (P = .069).
Multivariable logistic regression analysis (Table 5) revealed
that the initial use of anti–CTLA-4 was associated with
a lower risk of IMDC recurrence upon ICI resumption (P =
.002). Regardless of initial therapy, however, the resumption
of anti–PD-1/L1 therapy, as opposed to anti–CTLA-4 therapy,
was associated with a lower risk of IMDC recurrence (P =
.019). In addition, patients who required immunosuppres-
sive therapy for initial IMDC were more likely to experience
IMDC recurrence after the resumption of ICI therapy
(P = .019). Likewise, a long duration of IMDC symptoms in
the initial episode was associated with a higher risk of IMDC
recurrence (P = .031).
DISCUSSION
This multicenter study aimed to evaluate and characterize
the recurrence of IMDC after the resumption of ICI therapy
after a first occurrence of IMDC. Our approach of studying
recurrent ICI toxicity differs from previously published
studies in that our cohort comprised patients with different
types of cancer who received different types of ICI therapy.
Although such an approach limits in-depth analysis of
oncologic outcomes, it allows for generalizable data about
the toxicity profile of ICIs irrespective of cancer type. We
TABLE 2. Characteristics of Recurrent IMDC on the Basis of Resumed ICI Therapy
Resumed ICI Therapy, No. (%)
Characteristic Anti–CTLA-4 Monotherapy Anti–PD-1/L1 Monotherapy P
No. of patients 32 135
Recurrence of IMDC symptoms 14 (44) 43 (32) .302
Time from ICI resumption to IMDC recurrence, days (IQR) 26 (2-43) 79 (27-141) .024
Treatment of IMDC recurrence .307
Symptomatic only 3 (9) 8 (6)
Corticosteroid 8 (25) 31 (23)
Infliximab or vedolizumab add-on 3 (9) 4 (3)
Grade of recurrent diarrhea* .497
1 2 (6) 9 (7)
2 11 (34) 29 (22)
3-4 1 (3) 5 (4)
Grade of recurrent colitis* .388
1 7 (22) 23 (17)
2-3 6 (19) 20 (15)
Abbreviations: CTLA-4, cytotoxic T-cell lymphocyte-4; ICI, immune checkpoint inhibitor; IMDC, immune-mediated diarrhea and colitis; IQR,
interquartile range; PD-1/L1, programmed cell death 1 or ligand 1.



























FIG 1. Recurrence of immune-mediated diarrhea and colitis (IMDC)
after immune checkpoint inhibitor (ICI) resumption. CTLA-4, cytotoxic
T-cell lymphocyte-4; PD-1/L1, programmed cell death 1 or ligand 1.
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found the incidence of recurrent IMDC to be lower in
patients who resumed an anti–PD-1/L1 agent than in those
who resumed an anti–CTLA-4 agent.
We found that IMDC after ICI resumption was mostly grade
1 to 2 in severity, irrespective of the ICI type resumed. This
finding agrees with the limited body of evidence about the
resumption of ICIs. In the study by Pollack et al,16 which
comprised 80 patients with melanoma previously treated
with a combination ICI regimen who developed a clinically
significant irAE and were rechallenged with anti–PD-1
therapy, the recurrence of grade 3/4 colitis was 3%. In
another study of eight patients with melanoma who were
previously treated with anti–PD-1 therapy and rechallenged
with an anti–PD-1 agent, recurrent grade 1 IMDC was
reported in one.21 In addition to melanoma, the resumption
of ICI therapy in patients with non–small-cell lung cancer
has been reported (two case series and one case
report).22-24 None of these three studies reported a re-
currence of grade 3/4 IMDC. The discrepancy between
these reports and our findings could be the result of the low
rate of high-grade initial IMDC in those reports because we
found that more severe IMDC is a predictor of recurrence.
In addition, because ICI use has become more widespread
and practitioners have become more comfortable with irAE
management, ICI rechallenge has broadened.
Recurrent IMDC in our cohort was generally manageable by
established treatment approaches. No serious AEs that led
to mortality were identified in this IMDC cohort. By contrast,
Pollack et al16 reported progression of a grade 2 rash as the
initial event to a grade 3 rash with anti–PD-1 resumption,
which evolved into fatal Stevens-Johnson syndrome.
Hence, although the severity of IMDC after resumption of
ICI therapy seems to be mild, caution should be practiced.
Close monitoring for progression in severity of irAEs should
prompt timely management efforts, including adequate
immunosuppressive therapy as well as ICI discontinuation
TABLE 3. Characteristics of Recurrent IMDC for Patients Who Required







No. of patients 47 10
Time from ICI resumption
to IMDC recurrence,
days (IQR)




Symptomatic only 2 (4) 9 (90)
Corticosteroid 39 (83) 0 (0)
Infliximab or
vedolizumab add-on




1 3 (6) 8 (80)
2 38 (81) 2 (20)
3-4 6 (13) 0 (0)
Abbreviations: ICI, immune checkpoint inhibitor; IMDC, immune-mediated
diarrhea and colitis; IQR, interquartile range.
*Grades of diarrhea and colitis were determined by Common Terminology
Criteria for Adverse Events (version 5.0).
TABLE 4. Univariable Logistic Regression Analysis of IMDC Recurrence
Covariate Odds Ratio 95% CI P
Age 1.02 0.99 to 1.04 .187
Male sex 1.55 0.79 to 3.02 .199
Cancer stage III 0.28 0.08 to 0.99 .049
Duration of initial ICI treatment 1.00 0.99 to 1.00 .960
Anti–CTLA-4 initial therapy 0.50 0.26 to 0.95 .034
Resumption of anti–PD-1/L1 therapy 0.62 0.28 to 1.37 .236
Time from ICI stop to resumption 1.00 0.99 to 1.00 .843
Required immunosuppressive therapy initially 3.25 1.49 to 7.9 .003
Required infliximab or vedolizumab initially 2.57 1.07 to 6.19 .035
Grade of initial diarrhea*
2 2.39 0.97 to 5.93 .058
3-4 3.39 1.39 to 8.19 .007
Duration of initial IMDC symptoms 1.01 1.00 to 1.02 .035
Other non-GI irAEs 0.65 0.34 to 1.24 .190
Inflammation on endoscopy of the initial IMDC 2.61 0.93 to 7.31 .069
Abbreviations: CTLA-4, cytotoxic T-cell lymphocyte-4; ICI, immune checkpoint inhibitor; IMDC, immune-mediated diarrhea and colitis; irAE,
immune-related adverse event; PD-1/L1, programmed cell death 1 or ligand 1.
*Grades of diarrhea and colitis were determined by Common Terminology Criteria for Adverse Events (version 5.0).
2742 © 2019 by American Society of Clinical Oncology Volume 37, Issue 30
Abu-Sbeih et al
Downloaded from ascopubs.org by EAST CAROLINA UNIVERSITY on April 22, 2020 from 098.235.194.237
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
if deemed appropriate. In the setting of IMDC, colon biopsy of
mucosal ulcerations and nonulcerative inflammation, as well
as seemingly normal mucosal areas, on colonoscopy can
help to identify active inflammation and guide the duration of
immunosuppressive therapy.11,12,25
Our findings on multivariable analysis that anti–CTLA-4
therapy resumption was associated with an increased risk
of IMDC recurrence, whereas prior anti–CTLA-4 use was
a predictor of low risk of IMDC recurrence, hint at the relative
significance of prior and resumed ICI therapy and their
impact on toxicity recurrence. The clinical implication of
this observation should be taken into consideration when
planning ICI resumption in patients in whom previous ICI
therapy failed or had to be terminated altogether because of
AEs. Similarly, Pollack et al16 concluded that patients with
colitis and hypophysitis can safely resume anti–PD-1 ICI
therapy. In real-life settings, however, treatment decisions
are made on a per-patient basis, depending on comorbid
conditions and cancer therapy options.
Timely recognition and treatment of IMDC are critical to
sustain ICI therapy.31 To achieve this goal, the use of
potent nonsteroidal immunosuppressive therapy, such
as infliximab or vedolizumab, may be considered, al-
though the long-term effect of such drugs on cancer
outcomes is not yet known.10,26 A new IMDC treatment
strategy with great promise and no known immunosup-
pressive effect is fecal microbiota transplantation, which
was found by our group to be a novel treatment of
immunosuppression-refractory IMDC.27
Our findings reveal that even upon resumption of anti–
CTLA-4 therapy, the risk of severe IMDC seems to be
acceptable. Although resumption of anti–PD-1/L1 ther-
apy is more desirable when limitation of the toxicity profile
is among the major goals of care, the presumed toxicity
risk associated with anti–CTLA-4 therapy should not
prevent clinicians from considering resumption of these
drugs when this may be the only resort for prolonging
survival. In addition, patients who develop irAEs tend to
have high rates of response to ICI therapy, which are
sustained and may obviate ICI resumption.1,28-30 Hence,
the decision to resume ICI therapy in patients with an
ongoing durable response can be difficult, and more
studies are needed to outline the subset of patients who
will benefit from ICI resumption. Careful delineation of
goals of care should be discussed with patients before
treatment planning because this will help in making
decisions that are in line with each patient’s wishes and
optimize the subsequent quality of life of already de-
bilitated patients with cancer.1
In addition to the inherent fallacies of a retrospective
design, the patient cohort was heterogeneous because
our aim was to characterize the toxicity profile of ICI
resumption. One limitation of such an approach is the
inability to perform cancer-specific survival analyses.
Second, no predetermined criteria were used to decide
which patients could resume ICI therapy, and decisions
relied on the clinical judgment of the individual treating
physician. Third, because our cohort only consisted of
patients who resumed ICI therapy, we did not account for
patients who were deemed not to be candidates for ICI
resumption for any reason, which reflects an inherent
selection bias and limits the generalizability of our findings.
Fourth, because the focus of our study was IMDC, de-
termination of the characteristics and recurrence of non-GI
irAEs was not attempted. Fifth, practice standards could
have been different at the various institutions of this study
and could have had an impact on our data. Finally, because
of the limited sample size, multiple subgroup analyses may
have been underpowered.
In conclusion, one third of patients who resumed ICI
therapy after IMDC experienced recurrent IMDC that
was mostly mild and could be managed adequately with
immunosuppressive therapy. The lower risk of recurrent
IMDC upon resumption of ICI is intriguing and suggests
that ICI resumption in many patients is at least safe,
especially anti–PD-1/L1 therapy. Caution should be
practiced before resuming ICI therapy, especially in
patients with severe initial IMDC. Future prospective
studies with larger patient cohorts and predetermined
criteria for resumption should validate the safety and
efficacy of ICI resumption in the setting of IMDC.
TABLE 5. Multivariable Logistic Regression Analysis of IMDC Recurrence
Covariate Odds Ratio 95% CI P
Initial ICI type
Anti–CTLA-4 Reference
Anti–PD-1/L1 3.45 1.59 to 7.69 .002
ICI type resumed
Anti–CTLA-4 Reference
Anti–PD-1/L1 0.30 0.11 to 0.81 .019
Grade of initial diarrhea*
1 Reference
2 1.19 0.37 to 3.80 .775
3-4 2.19 0.66 to 7.29 .202
Required immunosuppressive
therapy initially
3.22 1.08 to 9.62 .019
Duration of initial IMDC symptoms 1.01 1.00 to 1.03 .031
Abbreviations: CTLA-4, cytotoxic T-cell lymphocyte-4; ICI, immune checkpoint
inhibitor; IMDC, immune-mediated diarrhea and colitis; PD-1/L1, programmed cell
death 1 or ligand 1.
*Grades of diarrhea and colitis were determined by Common Terminology
Criteria for Adverse Events (version 5.0).
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APPENDIX
TABLE A1. Included Patients From Each Institution
Institution No. of patients
The University of Texas MD Anderson Cancer Center 116
Ohio State University 19
University of Perugia 18
Cleveland Clinic Foundation 10
Johns Hopkins University 3
East Carolina University 1
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